ERBB2 and breast cancer: Currently, there are several other agents under clinical development for treating HER2-low BC, including T-Dxd combined with nivolumab, T-Dxd combined with Durvalumab, trastuzumab duocarmazine, disitamab vedotin (RC-48), ARX788, A166, FS-1502 and zenocutuzumab [20].